Shots:
- Roche reports an exploratory analysis of P-III IMvigor010 study assessing efficacy and safety of adjuvant treatment with Tecentriq vs observation in 809 people with MIUC, who are at high risk of recurrence following resection
- Results: in people with ctDNA, DFS Median (5.9 vs 4.4 mos.); median OS (25.8 vs 15.8 mos.). As presented in ASCO, the study did not meet its 1EPs of DFS (19.4 vs 16.6 mos.) in IIT population
- In general, people with MIUC who had detectable ctDNA were more likely to benefit from treatment with adjuvant Tecentriq monothx. compared with those without ctDNA
Click here to read full press release/ article | Ref: Roche | Image: Mint
The post Roche Presents Results of Tecentriq (atezolizumab) in P-III IMvigor010 Study for MIUC at ESMO 2020 first appeared on PharmaShots.
